{"id":"alpharix-tetra","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Myalgia"}]},"_chembl":{"chemblId":"CHEMBL36985","moleculeType":"Small molecule","molecularWeight":"800.59"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As an mRNA vaccine platform, Alpharix Tetra encodes antigens that are translated by host cells to trigger both CD8+ T-cell and antibody-mediated immune responses. The 'Tetra' designation suggests it targets four distinct antigens or disease variants, leveraging Moderna's modular mRNA technology to address multiple pathogens or tumor-associated antigens in a single therapeutic formulation.","oneSentence":"Alpharix Tetra is a multivalent mRNA vaccine designed to stimulate immune responses against multiple disease targets simultaneously.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:44:23.415Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Indication under investigation in Phase 3 (specific indication not publicly disclosed)"}]},"trialDetails":[{"nctId":"NCT06602024","phase":"PHASE3","title":"A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2024-09-16","conditions":"Seasonal Influenza","enrollment":40817},{"nctId":"NCT06716567","phase":"PHASE4","title":"Maternal Determinants of Immunity to Influenza","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Saint Pierre","startDate":"2020-11-16","conditions":"Vaccination; Infection, Maternal-Fetal Relations, Influenza","enrollment":109}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Alpharix® Tetra","genericName":"Alpharix® Tetra","companyName":"ModernaTX, Inc.","companyId":"modernatx-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"Alpharix Tetra is a multivalent mRNA vaccine designed to stimulate immune responses against multiple disease targets simultaneously. Used for Indication under investigation in Phase 3 (specific indication not publicly disclosed).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}